M.Á. Climent

569 total citations · 1 hit paper
11 papers, 378 citations indexed

About

M.Á. Climent is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M.Á. Climent has authored 11 papers receiving a total of 378 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 7 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M.Á. Climent's work include Bladder and Urothelial Cancer Treatments (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Urinary and Genital Oncology Studies (3 papers). M.Á. Climent is often cited by papers focused on Bladder and Urothelial Cancer Treatments (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Urinary and Genital Oncology Studies (3 papers). M.Á. Climent collaborates with scholars based in Spain, United States and Netherlands. M.Á. Climent's co-authors include Joaquim Bellmunt, Dean F. Bajorin, Daniel P. Petrylak, Toni K. Choueiri, David I. Quinn, David J. Vaughn, Yves Fradet, Andrea Necchi, Rodolfo F. Perini and Ronald de Wit and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

M.Á. Climent

10 papers receiving 374 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

2019 306 citations Yves Fradet, Joaquim Bellmunt et al. Annals of Oncology profile →

Peers

M.Á. Climent

SURGE

ONCOL

PRM

Sumika Matsukita Japan

Mauro Marques Barbosa Brazil

Julie Meilleroux France

Yong Fang China

Chihiro Fushimi Japan

Juro Nakanishi Japan

Michiel Simon Van Der Heijden Netherlands

Arnab Basu United States

Ecaterina F. Tamas United States

Taro Yamato Japan

Sumika Matsukita Japan

M.Á. Climent

110 ×0.4

SURGE

99 ×0.4

ONCOL

49 ×0.5

PRM

106 ×2.8

25 ×1.1

Citations per year, relative to M.Á. Climent M.Á. Climent (= 1×) peers Sumika Matsukita

Countries citing papers authored by M.Á. Climent

Since Specialization

Citations

This map shows the geographic impact of M.Á. Climent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.Á. Climent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.Á. Climent more than expected).

Fields of papers citing papers by M.Á. Climent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.Á. Climent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.Á. Climent. The network helps show where M.Á. Climent may publish in the future.

Co-authorship network of co-authors of M.Á. Climent

This figure shows the co-authorship network connecting the top 25 collaborators of M.Á. Climent. A scholar is included among the top collaborators of M.Á. Climent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.Á. Climent. M.Á. Climent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Rodríguez‐Vida, Alejo, Begoña P. Valderrama, Daniel Castellano, et al.. (2024). Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 9(9). 103690–103690.

Candela‐Cantó, Santiago, J. Hinojosa, Jordi Muchart, et al.. (2024). Temporo-Parieto-Occipital Disconnection by Robot-Assisted Magnetic Resonance Imaging–Guided Laser Interstitial Thermal Therapy for Refractory Epilepsy in a Pediatric Patient: Proof-of-Principle Case Report and Surgical Nuances. World Neurosurgery. 187. 124–132. 1 indexed citations

Bellmunt, Joaquim, Ronald de Wit, Yves Fradet, et al.. (2020). 747P Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052. Annals of Oncology. 31. S580–S581. 5 indexed citations

Fradet, Yves, Joaquim Bellmunt, David J. Vaughn, et al.. (2019). Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Annals of Oncology. 30(6). 970–976. 306 indexed citations breakdown →

Bellmunt, Joaquim, Ronald de Wit, David J. Vaughn, et al.. (2018). Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. Annals of Oncology. 29. viii320–viii321. 2 indexed citations

Necchi, Andrea, Joaquim Bellmunt, Ronald de Wit, et al.. (2017). Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study. European Journal of Cancer. 72. S2–S2. 3 indexed citations

Climent, M.Á., et al.. (2012). Long stabilization of sarcomatoid renal cell carcinoma treated with sorafenib. Actas Urológicas Españolas (English Edition). 36(6). 385–386. 1 indexed citations

Aparicio, Jorge, José L. García-Puche, M. Lomas, et al.. (2006). Prognostic factors for relapse in stage I seminoma managed by surveillance or adjuvant carboplatin: A multivariate analysis on 588 cases. Journal of Clinical Oncology. 24(18_suppl). 4552–4552. 3 indexed citations

Fernández-Martos, Carlos, Ivonne Romero, Jorge Aparicio, et al.. (2006). Preoperative uracil/tegafur and concomitant radiotherapy in locally advanced rectal (LAR) cancer: Updated results with a median follow-up of 5 years and analysis of prognostic factors (PF). Journal of Clinical Oncology. 24(18_suppl). 3573–3573. 1 indexed citations

10.

Baselga, José, M.Á. Climent, Aňa Lluch, et al.. (2004). Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC). European Journal of Cancer Supplements. 2(3). 132–132. 23 indexed citations

11.

Lluch, J. R. Germá, et al.. (1993). Treatment of Stage I Testicular Tumours. British Journal of Urology. 71(4). 473–477. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact